Fedratinib (Standard)

Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].

Product Specifications

CAS Number

[936091-26-8]

Product Name Alternative

TG-101348 (Standard) ; SAR 302503 (Standard)

UNSPSC

12352005

Target

Apoptosis; JAK; Reference Standards

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O

Molecular Formula

C27H36N6O3S

Molecular Weight

524.68

References & Citations

[1]Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13 (4) :311-20.|[2]Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13 (4) :321-30.